Industry News
IQnovate to move to ASX
Contract medical company IQnovate (NSX:IQN) will delist from the NSX and move its public share listing to the ASX. [ + ]
Remember me: immune cell discovery could improve vaccines
Researchers at the Walter and Eliza Hall Institute have revealed the process by which a specialised immune cell produces immune memory, which could lead to improvements in vaccines. [ + ]
Merged drug developer nears ASX listing
Bioxyne (ASX:BSN), created from the merger of Hunter Immunology and Probiomics (ASX:PCC), is scheduled to list on the ASX in April. [ + ]
Pharmaxis signs EU distribution deal for Bronchitol
Pharmaxis (ASX:PXS) has signed a three-year deal with Aravo Healthcare covering distribution of its cystic fibrosis treatment across Europe. [ + ]
Agenix on track for hepatitis B drug trial
Melbourne's Agenix (ASX:AGX) expects to be on time with an application to conduct a phase I trial of a prospective hepatitis B treatment in China. [ + ]
Synchrotron funding to support ongoing research
The Australian Synchrotron has yesterday secured a $100 million, allowing the Melbourne-based facility to continue research, after the Federal and state governments pledged contributions. [ + ]
Biota antiviral batters the common cold
Biota Holdings (ASX:BTA) has revealed the results of a successful phase IIb trial of its common cold treatment candidate, vapendavir. [ + ]
Alchemia finalising oncology spin-off
Brisbane-based Alchemia (ASX:ACL) is in the last stages of planning for the proposed spin-off and IPO of its oncology unit. [ + ]
iSonea to trial wheeze diagnostic in children
iSonea (ASX:ISN) will conduct a post-market trial of its WheezeoMeter diagnostics tool in patients too young for the traditional spirometry method. [ + ]
Australian Synchrotron beams on with $100m injection
$100 million in funding from the Australian, New Zealand and Victorian governments has saved the Australian Synchrotron from possible closure. [ + ]
Drug cocktail floors malaria
A combination treatment of anti-malarial drugs given intermittently over 12 months can cut malaria infections by up to 30 per cent in infants. [ + ]
Agreement secures future of the Australian Synchrotron
The future of one of the nation’s landmark research facilities - the Australian Synchrotron - has been secured under a $100 million agreement between the Australian and Victorian governments. [ + ]
Free listing on Australian biotech and medtech directories
AusBiotech invites Australian companies to list their biotechnology and medical technology companies free on two national directories. [ + ]
Research opens way for tailoring medications to patients
International research co-authored by the University of Otago, Christchurch (UOC) has unravelled a century-old scientific mystery, opening the way to significant improvements in the way drugs are delivered to the body. [ + ]
Australian Academy of Science elects new Fellows
The Australian Academy of Science has issued its annual list of new Fellows, admitting 21 more scientists to its ranks. [ + ]
